39 results
6-K
EX-99.1
EVAX
Evaxion Biotech A/S
27 Mar 24
Evaxion Announces Business Update and Full Year 2023 Financial Results
8:30am
annual J.P. Morgan Healthcare Conference.
February 27:
Chief AI Officer, Andreas Holm Mattsson, participated in a panel discussion at the Sachs Associates
6-K
EX-99.1
EVAX
Evaxion Biotech A/S
19 Mar 24
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
8:17am
that can be intelligently combined into AI prediction models to address complex healthcare issues related to the immune system. With the AI prediction
F-1/A
EVAX
Evaxion Biotech A/S
30 Jan 24
Registration statement (foreign) (amended)
3:16pm
and PD-L1 tumor expression.
This AI model shows promise in reducing clinical development risks and enhancing benefits for patients and healthcare payers … and addressing the significant healthcare burden. Ongoing efforts aim to further refine and validate AI-DeeP™ by accumulating more data, enhancing its
6-K
EX-99.1
EVAX
Evaxion Biotech A/S
24 Jan 24
Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
2:11pm
step forward in our commitment to improving healthcare through innovative and AI-powered approaches. We are already seeing significant interest in ERV
F-1
jk87o9rlsan5ea
12 Jan 24
Registration statement (foreign)
5:17pm
6-K
EX-99.1
zvsqx wkgf87f
19 Dec 23
Evaxion Announces Business Update and Third Quarter 2023 Financial Results
4:45pm
6-K
EX-99.1
sog4yjz62ctx tl3k
15 Nov 23
Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy
8:00am
6-K
EX-99.2
xes 3d6xeoldo2
27 Sep 23
Current report (foreign)
4:45pm
6-K
EX-99.2
20gr9czst4ghcjht
11 Aug 22
Current report (foreign)
4:30pm
6-K
EX-99.2
9sehx5c4 pdg1g
12 May 22
Current report (foreign)
4:35pm
6-K
EX-99.2
w4u82igcva
10 Nov 21
Current report (foreign)
4:40pm
424B4
8av7nzugm69 hcj
5 Nov 21
Prospectus supplement with pricing info
4:47pm
F-1/A
b5cvcqisqon57p
3 Nov 21
Registration statement (foreign) (amended)
7:50am
CORRESP
sm8uyv8b pylrgqgy3
3 Nov 21
Correspondence with SEC
12:00am
CORRESP
6n953lpx2x
29 Oct 21
Correspondence with SEC
12:00am
F-1
q31zxvm2 3xm0c2f6pma
26 Oct 21
Registration statement (foreign)
7:02am
6-K
EX-99.2
5b1p5prlasfq 64zldq
25 Oct 21
Evaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA® (pembrolizumab) in Patients with Melanoma
6:00am